Eli Lilly and Company (NYSE:LLY) Shares Sold by Washington Trust Advisors Inc.

Washington Trust Advisors Inc. decreased its position in Eli Lilly and Company (NYSE:LLY) by 9.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,105 shares of the company’s stock after selling 111 shares during the period. Washington Trust Advisors Inc.’s holdings in Eli Lilly and Company were worth $644,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $3,416,206,000. Moneta Group Investment Advisors LLC lifted its position in Eli Lilly and Company by 102,752.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after buying an additional 5,440,731 shares during the last quarter. Morgan Stanley boosted its stake in Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after buying an additional 3,691,436 shares during the period. Imprint Wealth LLC increased its position in shares of Eli Lilly and Company by 53,716.8% during the second quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock valued at $175,120,000 after acquiring an additional 1,747,946 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $445,944,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of several research reports. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Barclays boosted their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Bank of America lifted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Finally, BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $689.52.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 195,055 shares of company stock valued at $125,254,657 over the last three months. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.6 %

Shares of NYSE:LLY traded up $4.53 during trading on Thursday, hitting $782.71. 1,696,167 shares of the company’s stock were exchanged, compared to its average volume of 3,210,316. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 1-year low of $334.58 and a 1-year high of $800.78. The firm has a market cap of $743.70 billion, a P/E ratio of 135.99, a PEG ratio of 1.70 and a beta of 0.34. The firm has a 50-day moving average price of $727.96 and a two-hundred day moving average price of $636.01.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter in the previous year, the firm posted $2.09 earnings per share. The business’s revenue was up 28.1% on a year-over-year basis. Equities analysts predict that Eli Lilly and Company will post 12.42 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.